Reverse Merger with Protara and Recapitalization (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Jan. 01, 2020 shares
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Reverse stock split	On January 9, 2020, in connection with, and prior to the completion of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding.
Common shares exchange ratio	0.190756
Common stock outstanding	2,627,533
Shares available for issuance	20,365
Pre merger shares	557,631
Reverse business combination	1,033,907
Description of ownership rights	Immediately after the consummation of the Merger and prior to the consummation of the Proteon Private Placement, the former stockholders and option holders of Private ArTara owned, or held rights to acquire, approximately 75.2% of the fully diluted common stock of Protara, with Protara Therapeutics, Inc.’s stockholders and option holders immediately prior to the Merger owning approximately 24.8% of the fully-diluted common stock of Protara.
Goodwill (in Dollars) | $		$ 150
Prepaid expenses (in Dollars) | $	$ 78
Accrued expenses (in Dollars) | $	77
Fair value of net assets (in Dollars) | $	$ 34,533
2017 Equity Incentive Plan [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Shares available for issuance	219,699
2014 Equity Incentive Plan [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Shares available for issuance	398,604		1,048,300
Common Stock [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Common shares exchange ratio	0.190756
Private Placement [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Subscription agreement, description	(i) 3,879.356 of shares of Protara Therapeutics, Inc.’s Series 1 Convertible Non-Voting Preferred Stock at a purchase price of approximately $7,011.47 per share for gross proceeds of $27,200 and proceeds, net of issuance costs, of $25,319, (ii) 1,896,888 shares of Protara Therapeutics, Inc.’s common stock at a purchase price of approximately $7.01 per share for gross proceeds of $13,300 and proceeds, net of issuance costs, of $12,413 and (B) Private ArTara issued in a private placement immediately prior to the Merger (the “ArTara Private Placement”) 284,875 shares of Private ArTara common stock (post-Exchange Ratio basis) at a purchase price of approximately $7.01 per share (post-Exchange Ratio basis) (together with the Proteon Private Placement, the “Private Placements”) for gross proceeds of $2,000 and proceeds, net of issuance costs, of $1,867. The shares issued in the Proteon Private Placement were registered for resale on a registration statement on Form S-3 filed and declared effective by the SEC on January 30, 2020.
Converted shares issued	18,954
Series A Convertible Preferred Stock [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Convertible preferred stock	476,276
Merger Agreement [Member]
Reverse Merger with Protara and Recapitalization (Details) [Line Items]
Common shares exchange ratio	0.190756